Emotions From Salivary Biomarkers in an Architectural Context
Condition(s) studied
Investigational drug(s) / intervention(s)
Bio-fluid analysis for the measurement of salivary biomarkers linked to emotions: Saliva of participants will be sampled for analysis of biomarkers of interest (DHEA, oxytocin, cortisol, alpha-amylase, serotonin, and dopamine) using enzymatic dosage methods or ELISA-type methods carried out using commercial kits.
Study summary
Architecture influences our well-being. People's behavior and mood changes in different spaces are directly related to the architectural qualities of the built environment. Neuroarchitecture is a discipline that combines neuroscience and architecture to design spaces adapted to the psychological and physiological needs of users. Several studies related to neuroarchitecture have been conducted according to different architectural parameters such as style, natural environment, lighting, color, and sunlight pattern. Recent studies show that emotional states can be evaluated by physiological responses. This physiological regulation comes from the action of enzymes and hormones that represent the activity of the autonomic nervous system. Measuring specific biomarkers through non-invasive biological tests in saliva provides physiological data on an individual's emotional state in response to stimuli, particularly visual or tactile.
Eligibility
Primary outcome measure(s)
- Evaluate the variation of salivary biomarkers, which may be linked to emotions (positive or negative), before and after interaction with an architectural work. — 2 years
Evaluate the variation of salivary biomarkers, which may be linked to emotions (positive or negative), before and after interaction with an architectural work. This exposure includes a combination of visual, tactile, and/or olfactory stimuli.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Sys2Diag - Umr9005 Cnrs/Alcen | Montpellier | France |
More Sys2Diag trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07507266 on ClinicalTrials.gov ↗ ← All trials in France